NASDAQ:BLFS - BioLife Solutions Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$16.36 -0.14 (-0.85 %)
(As of 04/21/2019 04:00 PM ET)
Previous Close$16.36
Today's Range$15.8121 - $16.48
52-Week Range$6.92 - $26.35
Volume174,856 shs
Average Volume164,452 shs
Market Capitalization$305.11 million
P/E Ratio116.86
Dividend YieldN/A
Beta1.62
BioLife Solutions, Inc. develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death. The company offers HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications; and CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 for cryopreservation of stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services; and contract aseptic manufacturing formulation, filling, and finishing services for liquid media products. It markets its products to the regenerative medicine, bio-banking, and drug discovery markets, including hospital-based stem cell transplant centers, pharmaceutical companies, cord blood and adult stem cell banks, and hair transplant centers, as well as suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. The company markets and sells its products directly using its sales force, as well as through biolifesolutions.com; and through various regional distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

Receive BLFS News and Ratings via Email

Sign-up to receive the latest news and ratings for BLFS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLFS
CUSIPN/A
Phone425-402-1400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$19.74 million
Cash Flow$0.1696 per share
Book Value$2.33 per share

Profitability

Net Income$3.27 million

Miscellaneous

Employees40
Market Cap$305.11 million
Next Earnings Date5/9/2019 (Estimated)
OptionableNot Optionable

BioLife Solutions (NASDAQ:BLFS) Frequently Asked Questions

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

How were BioLife Solutions' earnings last quarter?

BioLife Solutions Inc (NASDAQ:BLFS) posted its earnings results on Thursday, March, 14th. The medical equipment provider reported $0.04 EPS for the quarter, hitting the Zacks' consensus estimate of $0.04. The medical equipment provider had revenue of $5.46 million for the quarter, compared to analysts' expectations of $5.47 million. BioLife Solutions had a return on equity of 11.15% and a net margin of 16.54%. View BioLife Solutions' Earnings History.

When is BioLife Solutions' next earnings date?

BioLife Solutions is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for BioLife Solutions.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions issued an update on its FY 2019 earnings guidance on Thursday, March, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $27-30 million, compared to the consensus revenue estimate of $28.04 million.

What price target have analysts set for BLFS?

4 brokerages have issued twelve-month price objectives for BioLife Solutions' shares. Their forecasts range from $5.00 to $26.00. On average, they expect BioLife Solutions' stock price to reach $17.75 in the next year. This suggests a possible upside of 8.5% from the stock's current price. View Analyst Price Targets for BioLife Solutions.

What is the consensus analysts' recommendation for BioLife Solutions?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioLife Solutions.

What are Wall Street analysts saying about BioLife Solutions stock?

Here are some recent quotes from research analysts about BioLife Solutions stock:
  • 1. According to Zacks Investment Research, "BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on their proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. " (3/19/2019)
  • 2. Maxim Group analysts commented, "BioLife announced that the company increased its stake in SAVSU $5M investment. The company also has an 18-month option to acquire the remaining 56%. In our view this is a strategic positive and the first step in management executing its plan to increase its share of the per-dose-spend in cell therapy. As such, shares should be up…not down, in our view." (9/5/2018)
  • 3. Northland Securities analysts commented, "We remain constructive on this name. Besides being a lower-risk diversified pseudo-biotech play, BioLife also has the unique opportunity of increasing its revenues per customer, therefore increasing its product stickiness. the most important takeaway from the company call was the increased focus on M&A. The company announced a $20M investment from an investor, bringing the total ownership of that investor to 14%. This investment allows BioLife to start focus on a few M&A targets pretty aggressively. The goal of an M&A strategy would be to increase the ecosystem in which more dollars per customer can be captured. Currently, BioLife generates about $50 – $100/ customer, and a targeted M&A strategy could help the company go 5 – 10x of current revenues/customer." (8/10/2018)

Has BioLife Solutions been receiving favorable news coverage?

Media stories about BLFS stock have been trending neutral on Sunday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioLife Solutions earned a news impact score of 0.4 on InfoTrie's scale. They also assigned news stories about the medical equipment provider a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term.

Who are some of BioLife Solutions' key competitors?

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Canopy Growth (CGC), Twilio (TWLO), NVIDIA (NVDA), Micron Technology (MU), Terra Tech (TRTC), Square (SQ), Exelixis (EXEL), Juno Therapeutics (JUNO), Progenics Pharmaceuticals (PGNX) and Alibaba Group (BABA).

Who are BioLife Solutions' key executives?

BioLife Solutions' management team includes the folowing people:
  • Mr. Michael P. Rice, Pres, CEO & Director (Age 56)
  • Mr. Roderick de Greef, CFO & Sec. (Age 59)
  • Dr. Aby J. Mathew, Chairman of Scientific Advisory Board, Chief Technology Officer and Sr. VP (Age 47)
  • Ms. Karen Foster, VP of Operations (Age 59)
  • Mr. Kevin O'Donnell, VP of Cold Chain Standards, Practices & Compliance

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by many different of retail and institutional investors. Top institutional investors include Roubaix Capital LLC (0.24%), Tibra Equities Europe Ltd (0.12%) and Conestoga Capital Advisors LLC (0.07%). Company insiders that own BioLife Solutions stock include Andrew G Hinson, Greef Roderick De, Joseph C Schick, Michael Rice, Raymond W Cohen, Thomas Girschweiler, Todd Berard and Walter Villiger. View Institutional Ownership Trends for BioLife Solutions.

Which major investors are buying BioLife Solutions stock?

BLFS stock was purchased by a variety of institutional investors in the last quarter, including Roubaix Capital LLC, Tibra Equities Europe Ltd and Conestoga Capital Advisors LLC. View Insider Buying and Selling for BioLife Solutions.

How do I buy shares of BioLife Solutions?

Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $16.36.

How big of a company is BioLife Solutions?

BioLife Solutions has a market capitalization of $305.11 million and generates $19.74 million in revenue each year. The medical equipment provider earns $3.27 million in net income (profit) each year or $0.14 on an earnings per share basis. BioLife Solutions employs 40 workers across the globe.

What is BioLife Solutions' official website?

The official website for BioLife Solutions is http://www.biolifesolutions.com.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at 425-402-1400 or via email at [email protected]


MarketBeat Community Rating for BioLife Solutions (NASDAQ BLFS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  173 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  296
MarketBeat's community ratings are surveys of what our community members think about BioLife Solutions and other stocks. Vote "Outperform" if you believe BLFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLFS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel